-
公开(公告)号：EP3132792B1
公开(公告)日：2019-09-11
申请号：EP16179626.3
申请日：2006-11-20
IPC分类号： A61K31/00 , A61K31/135 , A61K31/138 , A61K31/423 , A61K31/4525 , A61K31/485 , A61K31/55 , A61K31/551 , A61K31/7048 , A61K45/06 , A61P3/10 , A61K38/28 , A61K31/445 , A61K31/519 , A61K31/5415 , A61K31/5513 , A61K31/554 , A61K31/35 , A61K31/137 , A61K31/357
-
32.发明公开
公开(公告)号：EP3528814A1
公开(公告)日：2019-08-28
申请号：EP17862888.9
申请日：2017-10-18
IPC分类号： A61K31/519 , A61K31/551 , A61K31/5513 , C07D487/02 , C07D487/14 , C07D223/18
-
33.发明公开
公开(公告)号：EP3520786A1
公开(公告)日：2019-08-07
申请号：EP18182706.4
申请日：2018-07-10
申请人： Levit, Shmuel Boris
发明人： Levit, Shmuel Boris
IPC分类号： A61K31/19 , A61K31/197 , A61K31/403 , A61K31/4439 , A61K31/4985 , A61K31/513 , A61K31/5513 , A61P3/10
摘要： This invention applies to the field of medicine, namely to endocrinology, and can be used to treat type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase-4 (DPP-4) inhibitor, a proton pump inhibitor (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of the β-cells of the pancreas, presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons and is intended for the treatment of type 1 diabetes mellitus.
-
公开(公告)号：EP3512521A1
公开(公告)日：2019-07-24
申请号：EP17850399.1
申请日：2017-09-16
IPC分类号： A61K31/551 , A61K31/5513 , A61K9/20 , A61K9/22 , A61K9/30
-
公开(公告)号：EP3452024A1
公开(公告)日：2019-03-13
申请号：EP17723617.1
申请日：2017-05-04
IPC分类号： A61K9/70 , A61K31/137 , A61K31/5513 , A61K31/5517
-
公开(公告)号：EP3416649A1
公开(公告)日：2018-12-26
申请号：EP17753818.8
申请日：2017-02-16
发明人： DETKE, Michael , GLOFF, Carol , STRAUB, Julie
IPC分类号： A61K31/5513 , A61K31/00 , A61K31/444
CPC分类号： A61K31/5513 , A61K31/444 , A61K2300/00
摘要： The present invention is directed to compositions and methods for treating substance abuse disorders and addiction. In particular, this invention is directed to combinations of low doses of a Cortisol synthesis inhibitor, such as metyrapone, in combination with low doses of a benzodiazepine, such as oxazepam. The compositions and methods of the present invention include pharmaceutical compositions and methods that are safe and efficacious for treating animals and humans.
-
公开(公告)号：EP3402792A1
公开(公告)日：2018-11-21
申请号：EP16812677.9
申请日：2016-12-16
申请人： Merck Patent GmbH
发明人： DORSCH, Dieter , MUZERELLE, Mathilde , BURGDORF, Lars , WUCHERER-PLIETKER, Margarita , CZODROWSKI, Paul , ESDAR, Christina , TSAKLAKIDIS, Christos
IPC分类号： C07D413/14 , C07D403/04 , C07D403/14 , C07D407/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D497/10 , A61K31/436 , A61K31/4704 , A61K31/5377 , A61K31/5513 , A61P35/00
CPC分类号： C07D403/04 , C07D403/14 , C07D407/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D487/10 , C07D497/10
摘要： Compounds of the formula (I) in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
-
公开(公告)号：EP3027179B1
公开(公告)日：2018-10-17
申请号：EP14832172.2
申请日：2014-07-30
IPC分类号： A61K31/4196 , A61K31/422 , A61K31/5513 , A61K31/5517
CPC分类号： A61K31/4196 , A61K9/0056 , A61K9/006 , A61K31/422 , A61K31/473 , A61K31/5513 , A61K31/5517 , A61K47/02 , A61K47/32 , A61K47/38
摘要： An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the film comprises hydroxypropyl cellulose or a combination of hydroxypropyl cellulose and a polymer or copolymer of vinylpyrrolidone or a substituted vinylpyrrolidone as the water soluble polymer(s). A plasticizer, and optional additives selected from synthetic sweeteners, natural sweeteners, flavorants, antioxidants, colorants, and opacifiers, can be added to the disclosed film oral dosage forms.
-
公开(公告)号：EP2501695B1
公开(公告)日：2018-08-29
申请号：EP10831982.3
申请日：2010-11-03
发明人： GLICK, Gary D.
IPC分类号： C07D403/10 , C07D401/10 , C07D471/04 , C07D487/04 , A61K31/5513 , A61K31/437 , A61P9/10 , A61P9/12
CPC分类号： C07D471/04 , C07D401/10 , C07D403/10
摘要： The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.
-
公开(公告)号：EP3363439A2
公开(公告)日：2018-08-22
申请号：EP17206278.8
申请日：2011-10-24
IPC分类号： A61K31/5513 , A61K31/46 , A61K31/496 , A61P25/02 , C07D417/12 , C07D451/10 , C07D471/04 , C07D495/04
CPC分类号： A61K31/5513 , A61K31/46 , A61K31/496 , C07D417/12
摘要： Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.
-
-
-
-
-
-
-
-
-
搜索结果
897 条记录 (耗时 0.024 秒)
